Teligent, Inc. TLGT
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 16.10M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.44
- Beta
- 1.62
- Short ratio
- 0.36
- Inst. own
- 12.91%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.292697
- 200-d avg
- 0.457028
- 1y target
- 0.00
Key statistics
- Market cap
- 16.10M
- Enterprise value
- 127.38M
- Trailing P/E
- 0.00
- Forward P/E
- -0.44
- PEG ratio
- 0.00
- Price / sales
- 0.35
- Price / book
- 0.00
- EPS (TTM)
- -2.10
- Beta
- 1.62
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -197.78%
- Revenue (TTM)
- 46.30M
- Revenue growth
- -23.20%
- Free cash flow
- -8.94M
- Total cash
- 22.63M
- Total debt
- 118.53M
- Return on equity
- 0.00%
- Shares outstanding
- 92.82M
- Short % of float
- 2.48%
- 50-day average
- 0.292697
- 200-day average
- 0.457028
Analyst view
Consensus: hold
- Strong buy1
- Buy2
- Hold3
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 16, 2021 | Jun 1, 2021 | 0.00 | -0.14 | — | — |
| May 25, 2021 | Mar 1, 2021 | 0.00 | -0.20 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2020 | Craig-Hallum | down | Buy | Hold |
| Nov 25, 2020 | Raymond James | down | Outperform | Market Perform |
| Nov 25, 2020 | Raymond James | down | Strong Buy | Outperform |
| Nov 25, 2020 | Canaccord Genuity | main | Hold | Hold |
| Nov 25, 2020 | Canaccord Genuity | main | Hold | Hold |
| Nov 25, 2020 | Canaccord Genuity | down | Buy | Hold |
About Teligent, Inc.
Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's topical semi-solid and liquid products are used in various applications that range from cosmetics and cosmeceuticals; and the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. It sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was incorporated in 1977 and is based in Buena, New Jersey. On October 14, 2021, Teligent, Inc. along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- teligent.com
News
- TLGT Stock: Why The Price Substantially Fell
- Top Penny Stocks to Buy Right Now? 3 to Check Out This Month
- Stocks That Hit 52-Week Lows On Tuesday
- Teligent, Inc. (TLGT) CEO Tim Sawyer on Q2 2021 Results - Earnings Call Transcript
- Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update
- Stocks That Hit 52-Week Lows On Monday
- Teligent, Inc. Announces Adjournment of Annual Meeting of Stockholders
- Trading Biotech Penny Stocks? Check These 3 Out
- Teligent's (TLGT) CEO Tim Sawyer on Q1 2021 Results - Earnings Call Transcript
- Teligent: Q1 Earnings Insights
Your note
Sign in to keep a note on TLGT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEN MAIMON CAROLE S | Director | Purchase | May 29, 2019 | 16,000 |
| CELENTANO JOHN E | Director | Purchase | May 30, 2019 | 20,000 |
| CHAUDHURI BHASKAR MICHAEL | Director | Purchase | Jun 2, 2019 | 10,000 |
| FINIO DAMIAN | Chief Financial Officer | Purchase | Dec 13, 2018 | 10,000 |
| GALE JAMES C | Director | Purchase | May 30, 2019 | 419,624 |
| GRENFELL GARDNER JASON | Chief Executive Officer | Purchase | May 22, 2019 | 119,849 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Silverback Asset Management, LLC | 3.79% | 3,514,471 | 1.88M | Jun 29, 2021 |
| Eversept Partners, LP | 2.69% | 2,500,260 | 1.34M | Jun 29, 2021 |
| Nantahala Capital Management, LLC | 2.61% | 2,418,987 | 1.29M | Jun 29, 2021 |
| Vanguard Group, Inc. (The) | 0.99% | 920,875 | 492.58K | Jun 29, 2021 |
| Blackrock Inc. | 0.70% | 646,666 | 345.90K | Jun 29, 2021 |
| Geode Capital Management, LLC | 0.61% | 569,927 | 304.85K | Jun 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.93% | 865,731 | 463.08K | Jun 29, 2021 |
| Fidelity Extended Market Index Fund | 0.47% | 438,829 | 174.13K | Aug 30, 2021 |
| Fidelity Series Total Market Index Fund | 0.08% | 72,562 | 28.79K | Aug 30, 2021 |
| Fidelity NASDAQ Composite Index Fund | 0.07% | 69,134 | 27.43K | Aug 30, 2021 |
| USAA Mutual Fd Tr-Extended Market Index Fd | 0.02% | 14,333 | 7.67K | Jun 29, 2021 |
| Fidelity Total Market Index Fund | 0.01% | 9,911 | 3.93K | Aug 30, 2021 |